SARS‐CoV‐2 NSP7 inhibits type I and III IFN production by targeting the RIG‐I/MDA5, TRIF, and STING signaling pathways
Journal of Medical Virology · 2023
DOI: 10.1002/jmv.28561 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Jian Deng und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory for Experimental Teratology of Ministry of Education and Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong Un…. Hauptthemen laut MEDLINE: COVID-19, Interferon Type I. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a poor inducer of innate antiviral immunity, and the underlying mechanism still needs further investigation. Here, we reported that SARS‐CoV‐2 NSP7 inhibited the production of type I and III interferons (IFNs) by targeting the RIG‐I/MDA5, Toll‐like receptor (TLR3)‐TRIF, and cGAS‐STING signaling pathways. SARS‐CoV‐2 NSP7 suppressed the expression of IFNs and IFN‐stimulated genes induced by poly (I:C) transfection and infection with Sendai virus or SARS‐CoV‐2 virus‐like particles. NSP7 impaired type I and III IFN production activated by components of the cytosolic dsRNA‐sensing pathway, including RIG‐I, MDA5, and MAVS, but not TBK1, IKKε, and IRF3‐5D, an active form of IRF3. In addition, NSP7 also suppressed TRIF‐ and STING‐induced IFN responses. Mechanistically, NSP7 associated with RIG‐I and MDA5 prevented the formation of the RIG‐I/MDA5−MAVS signalosome and interacted with TRIF and STING to inhibit TRIF‐TBK1 and STING‐TBK1 complex formation, thus reducing the subsequent IRF3 phosphorylation and nuclear translocation that are essential for IFN induction. In addition, ectopic expression of NSP7 impeded innate immune activation and facilitated virus replication. Taken together, SARS‐CoV‐2 NSP7 dampens type I and III IFN responses via disruption of the signal transduction of the RIG‐I/MDA5−MAVS, TLR3‐TRIF, and cGAS‐STING signaling pathways, thus providing novel insights into the interactions between SARS‐CoV‐2 and innate antiviral immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory for Experimental Teratology of Ministry of Education and Advanced Medical Research Institute, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Department of Immunology, Key Laboratory of Infection and Immunity of Shandong Province, School of Basic Medical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.
- The Center for Infection and Immunity Study and Molecular Cancer Research Center, School of Medicine, Sun Yat-sen University, Shenzhen, Guangdong, China.
- Department of Neurology, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
ORCID-Profile: Chengjiang Gao, Pei-Hui Wang
Zitieren
APA
Deng, J., Zheng, Y., Zheng, S. N., Nan, M. L., Han, L., Zhang, J., Jin, Y., Pan, J. A., Gao, C., & Wang, P. H. (2023). SARS‐CoV‐2 NSP7 inhibits type I and III IFN production by targeting the RIG‐I/MDA5, TRIF, and STING signaling pathways. Journal of Medical Virology. https://doi.org/10.1002/jmv.28561
Vancouver
Deng J, Zheng Y, Zheng SN, Nan ML, Han L, Zhang J, et al. SARS‐CoV‐2 NSP7 inhibits type I and III IFN production by targeting the RIG‐I/MDA5, TRIF, and STING signaling pathways. Journal of Medical Virology. 2023. doi:10.1002/jmv.28561
BibTeX
@article{Deng2023,
author = {Deng, Jian and Zheng, Yi and Zheng, Sheng-Nan and Nan, Mei-Ling and Han, Lulu and Zhang, Jing and Jin, Yunyun and Pan, Ji-An and Gao, Chengjiang and Wang, Pei-Hui},
title = {SARS‐CoV‐2 NSP7 inhibits type I and III IFN production by targeting the RIG‐I/MDA5, TRIF, and STING signaling pathways},
journal = {Journal of Medical Virology},
year = {2023},
doi = {10.1002/jmv.28561}
}
EUVIMED